The oncology specialist will advance its lead drug candidate into Phase 2 trials with the proceeds of the $60m round, which featured existing investor Purdue Pharmaceuticals.
Kolltan Pharmaceuticals, a US-based developer of therapeutic cancer treatments, has closed a $60m series D round from investors including pharmaceutical company Purdue Pharma.
Other investors in the series D round were KLP Enterprises, Deerfield Capital Management, HBM Healthcare Investments and Osage University Partners.
Purdue also participated in Kolltan’s $40m series A round in 2009 and its $10m series B the following year. Kolltan has now raised $125m in total funding since it was founded in 2007 and its past investors…
